Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study.
作者信息
Huber W, Willmes K, Poeck K, Van Vleymen B, Deberdt W
机构信息
Department of Neurology, School of Logopedics, Rheinisch-Westfalische Technische Hochschule (RWTH), Braine-l'Alleud, Belgium.
出版信息
Arch Phys Med Rehabil. 1997 Mar;78(3):245-50. doi: 10.1016/s0003-9993(97)90028-9.
OBJECTIVE
To determine whether piracetam 4.8 g/day together with intensive language therapy improved language function more than language therapy alone.
DESIGN
Double-blind, placebo-controlled parallel group study.
SETTING
Referral speech and language clinic of a university department of neurology.
PATIENTS
Sixty-six inpatients with aphasia present between 4 weeks and 36 months.
INTERVENTIONS
Intensive language therapy for 6 weeks in all patients. Thirty-two patients received piracetam 4.8 g daily and 34 patients received placebo.
MAIN OUTCOME MEASURE
The Aachen Aphasia Test (AAT), a standardized procedure for evaluating the severity of aphasia, was performed at baseline and after 6 weeks' treatment.
RESULTS
In 50 patients evaluated for efficacy, a trend toward improvement in the active group was observed in all subtests of the AAT. This trend was statistically significant for absolute differences in recovery of "written language" and "profile level."
CONCLUSION
Piracetam appears to have a positive adjuvant effect on the recovery of aphasia in patients receiving intensive language therapy.
Zotero 插件